Moderna, Inc.
- mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222
- Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills.
The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Spikevax® is a registered trademark of Moderna.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential longer refrigerator shelf life and storage advantages of mRNA-1283 compared to Spikevax; and the ability of mRNA-1283 to maintain effectiveness compared to Spikevax. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Elise Meyer
Sr. Director, Corporate Communications
+1 617-852-7041
Elise.Meyer@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Declares Quarterly Dividend5.2.2025 07:50:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 5, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on February 28th to shareholders of record at the close of business on February 17th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's o
Preservica and Oyster IMS Partner to Future-Proof Microsoft 365 Data with Active Digital Preservation5.2.2025 04:00:00 CET | Press release
OXFORD, UK / ACCESS Newswire / February 5, 2025 / Preservica, the leader in Active Digital Preservation™ archiving, has today announced a partnership with Oyster IMS, an expert consultancy-led business serving transnational agencies, global enterprises, local authorities and SMEs. Oyster IMS is now an authorized reseller of Preservica's Enterprise and Preserve365® technology and will support Microsoft 365 customers adopting a strong information governance framework for high-value, long-term content and those preparing for AI implementations. As digital content continues to grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a strategic imperative, essential for cutting compliance risk and leveraging AI. This is the arena in which Oyster IMS works with a set of clients ranging from SMEs to multinationals, and from local authorities to international governmental bodies. "I'm delighted to establish a for
ToolsGroup Welcomes Supply Chain Leader Sean Elliott as Chief Executive Officer4.2.2025 15:15:00 CET | Press release
20-year industry veteran brings deep technical expertise and leadership to guide ToolsGroup's next phase of growth BOSTON, MA / ACCESS Newswire / February 4, 2025 / ToolsGroup, a global leader in supply chain and retail planning and optimization software, today announced the appointment of Sean Elliott as its new Chief Executive Officer, effective immediately. Elliott brings more than two decades of strategic leadership and technical expertise in supply chain software development and leadership to ToolsGroup. Most recently, he served as Co-CEO at Körber Supply Chain Software. At ToolsGroup, Elliott will focus on accelerating innovation, driving strategic business expansion, and strengthening its partnerships and ecosystem to deliver a best-in-class customer outcome and experience. "We are thrilled to welcome Sean to ToolsGroup," said Andrew Zbella, Principal at Accel-KKR and member of the Board of Directors. "His proven leadership, deep technical background and continued commitment to
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment4.2.2025 05:00:00 CET | Press release
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth. ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collab
IXOPAY Appoints Yasser Abou-Nasr as SVP of Product to Drive Execution and Scale4.2.2025 00:00:00 CET | Press release
Seasoned Fintech Leader Joins IXOPAY to Advance Product Innovation and Drive Scalable Growth in Payment Orchestration. LEHI, UT / ACCESS Newswire / February 4, 2025 / IXOPAY, a leading enterprise payment orchestration platform, announced the appointment of Yasser Abou-Nasr as SVP of Product. With over 16 years of senior product leadership in payments and fintech, Yasser joins IXOPAY to execute the company's strategic vision and scale its product offerings to meet the growing demand for seamless and secure payment solutions. Yasser brings a proven track record of driving product execution at scale, combined with deep expertise in product management, operational transformation, and the development of B2B SaaS platforms. His leadership will be instrumental in advancing IXOPAY's enterprise payment orchestration platform, enabling businesses worldwide to simplify, secure, and optimize their payment systems through scalable and flexible solutions. "Yasser's ability to execute and scale compl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom